Authors' reply
Dr Abu raises the question of autoantibodies against thyroid hormones having a role in the pathogenesis of the goitre of the patient we reported. This patient had supranormal thyroid stimulating hormone (TSH) 48 h after stopping multiple drug therapy with carbimazole, bromocriptine and levothyroxine, and normal TSH 2 months later. Since drug therapy had been instituted during the year before consultation, we can assume that TSH had probably been within the normal range during most of the 15year course of the patient's goitre.
Autoantibodies can be the dominant thyroid hormone transport protein in some sera' and have been causally related to hypothyroidisrrr', So, the possibility of increased thyroid hormone requirement acting as a goitrogen exists. Autoantibodies against thyroid hormones have been previously reported in association with goitre in patients with Hashimoto thyroiditis.' (where the understanding of goitre pathogenesis does not require the contribution of thyroid hormone autoantibodies) and in patients with nodular goitre", It is possible that thyroid hormone autoantibodies contribute to the goitre but it is Ann Clin Biochem \998: 35 difficult to demonstrate a causal role. First of all, it is impossible to know what appeared first in the clinical course. Second, nodular goitres with big nodules have become TSH-independent and nodules virtually never disappear with thyroid hormone treatments. So, although therapy with thyroid hormone decreases the level of autoantibodies" and, we can postulate, the disappearance of the goitrogen stimulus, we can not expect the definite proof of reversibility. In the patient we have reported, the size and nodular characteristic of the goitre prompted surgical therapy (bilateral subtotal thyrodectomy) with a pathological diagnosis of multinodular goitre. We do not have follow-up information on the level of autoantibodies against thyroid hormones. index, however, the Hitachi analysers use a measuring wavelength of 570 nm and a reference wavelength of 600 nm.
3 When the analyser detects any haemolysis the laboratory should not report the CK-MB result and should request a new specimen.
The preferred option is to obtain a 'blank' activity, which is then subtracted from the CK-MB reaction. This ensures correction of the AK effect. The Hitachi analysers offer the opportunity to perform a 'RATE B' method. A blank measurement is performed between 4 and 5 min after addition of the first reagent to the sample. The CK-MB reaction is started by addition of creatine phosphate as the second reagent. Our laboratory uses a CK-MB test with Merck Diagnostica (Merck KGaA, Darmstadt, Germany) Granutest based on the reversed CK-MB reaction which is also subjected to AK interference. We correct the CK-MB reaction by subtracting the blank measurement before reporting the CK-MB result (our CK-MB reference value is 15U/L). We reject the CK-MB results when haemolysis exceeds 70 umolfl, (4'5 g/L) free haemoglobin. Besides the AK effect from haemolysis, several samples appeared to have a very high AK effect at low Letters haemolysis index (Fig. I) . This can be explained by the fact that AK is found in high concentrations in nearly all tissues. Diadenosine pentaphosphate, present in the reagent, is a competitive inhibitor of the AK from erythrocytes and muscle but has less effect on the liver and kidney AK. In seven samples we measured an AK effect of more than 75 UjL. In six of these the total CK exceeded 1000 U fL, indicating muscle origin for the AK (CK reference value < 120UjL). These results confirm the necessity of using a blank subtraction because AK interference can also be caused by release of AK from muscle, liver and kidney. In this case the AK interference will not be detected by a haemolytic index measurement. Author's reply: haemolysis and CK-MB assay In his letter in response to our manuscript I Dr Harff correctly points out that all assays using the reverse reaction are more or less subject to interference from haemolysis. Dr Harff also points out that Hitachi analyzers also offer the opportunity to perform a 'RATE B' blank measurement to subtract the AK activity in the specimen. Our application originated in Germany and did not support the Rate B blanking method for the Hitachi 917 analyzer. Since that time we have discontinued CK-MB measurement by this method and now use a CK-MB mass assay. The wavelengths for estimating haemoglobin should have been 570 and 600 nm, those for our serum index screen were quoted in error.
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